CompletedPhase 3NCT03581591
Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets
Studying Autosomal dominant hypophosphatemic rickets
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Redwood Dermatology Sciences
- Principal Investigator
- Jeffrey Sugarman, MD PhDRedwood Dermatology Sciences
- Intervention
- Burosumab(biological)
- Enrollment
- 1 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2018 – 2019
Study locations (1)
- The Focus Center, PC, Clinton, Utah, United States
Collaborators
Ultragenyx Pharmaceutical Inc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03581591 on ClinicalTrials.gov